Furthermore, CLEC-2 levels were significantly lower in the luminal B HER2-positive and triple-negative subtypes compared to controls, aligning with the hypothesis that more aggressive breast cancer subtypes are associated with reduced CLEC-2 expression. This evidence concerns the gene ERBB2 and breast carcinoma.